Chronic pain, defined as pain lasting longer than three months, affects 100 million Americans each year. Estimates are that 5 to 8 million Americans use opioids for chronic pain. Other uses of opioids include acute pain, cancer-related pain, post-surgical pain, and vascular pain.
The FDA has also approved the use of opioids as antitussive and anti-diarrheal medications. Loperamide, also known as the over counter medication Imodium, is an opioid used to treat diarrhea and irritable bowel syndrome. It exerts this effect by decreasing intestinal motility and increasing absorption time.
Opioids such as codeine and dextromethorphan are useful as cough suppressants. Codeine is considered the standard cough suppressant against which new drugs get tested. Codeine is also considered a valuable antitussive as it provides additional benefits of analgesia and sedation.
The use of opioids for analgesia is controversial due to the risk of addiction and tolerance. In 2014, 2.5 million adults in the United States were misusing opioids. Signs of opioid addiction including cravings, obsessive thinking about opioids, and inability to refrain from opioid use. These behavioral changes, in turn, lead to functional and structural changes in the brain, which make it difficult to stop opioid use.
On another note, prescription opioids are known to serve as a gateway drug for heroin. From 2000 to 2003, the death rate from heroin overdose nearly tripled.
While discussing opioids, it’s important to examine the history which led to the opioid epidemic. In the mid-1990s, certain pharmaceutical companies funded non-profit organizations focused on pain management, which led to the belief that the medical community was undertreating chronic pain in some individuals and ultimately led to pain being considered the fifth vital sign. One of these companies also funded a program that led to a guide that stated that prescribers had exaggerated concerns about addiction to opioids. In 2004, encouraged by individuals with ties to the manufacturing of opioids, the Federation of American Medical Boards urged medical societies to punish prescribers who undertreated pain.
Physicians also played a role in the epidemic. Many "pill mills," where physicians overprescribed opioids and other controlled substances without medical justification, were run in states such as Florida in the mid-2000s. Since then, investigations have led to arrests and convictions of such physicians. However, one must note that surveys filled out by physicians show that many feel pressure to prescribe opioids due to the link between reimbursement and patient satisfaction of pain control. For this reason, the American Academy of Family Physicians and American Medical Association have both voted to drop pain as a vital sign.
"Opioid" is an umbrella term that represents all compounds that bind to opioid receptors, which includes compounds derived from poppy seeds, such as morphine and codeine, as well as synthetic opioids like fentanyl. Opioid receptors are found throughout the central and peripheral nervous systems and GI tract, regulating many functions in the body: pain, mood, stress, reward, gastrointestinal functions, and respiration.
There are three opioid receptors: mu, kappa, and delta. Mu receptors mediate most of the clinical and adverse effects of opioids: analgesia, sedation, euphoria, constipation, and respiratory distress. Activation of kappa receptors also leads to analgesia, dyspnea, and sedation. Research on the role of delta receptors is sparse.
Once activated, opioid receptors start a cascade that activates G proteins and inhibits adenylyl cyclase, ultimately leading to alterations in gene transcription. Opioid receptors work on both presynaptic and postsynaptic neurons. On presynaptic neurons, opioids close voltage-gated calcium channels, leading to decreased release of pain neurotransmitters such as glutamate and substance P. This ultimately reduces transmission of pain signals. Presynaptic opioid receptors on neurons in the ventral tegmental area inhibit the release of GABA, causing dopaminergic neurons to fire more frequently and creating feelings of euphoria. Postsynaptic opioid receptors open potassium channels, leading to hyperpolarization in cells that inhibits cell signaling.
Most opioids are full agonists at the mu receptor. Some, such as buprenorphine, butorphanol, and nalbuphine, are partial agonists. Tramadol, a weak opioid mu agonist, also inhibits serotonin and norepinephrine reuptake.
Opioids come in a number of forms and can be administered orally, rectally, topically (transdermal patches), intravenously, in the epidural space, and into the dura. The mode of administration and duration of action depend on lipophilicity and hydrophilicity of the opioid. For example, codeine can be administered via oral, intramuscular, and rectal routes. Oral codeine absorbs rapidly and reaches a peak concentration within one hour in most adults.
Opioids are frequently misused. Most commonly, individuals misuse these agents in tablets or capsule dose forms. However, some abusers alter the route of administration, inhaling or injecting crushed tablets to achieve a heightened or more rapid psychoactive effect and attenuate the rewarding effect of the drug. For this reason, the Food and Drug Administration has approved abuse-deterrent formulations of opioid prescriptions to prevent the tablets from being crushed.
Common side effects of taking opioids include:
Less common side effects include:
Narcotic bowel syndrome (NBS) occurs when individuals experience daily moderate to severe abdominal pain for three months or more. Patients may increase opioid intake to deal with the pain. Paradoxically, the abdominal pain often increases in response to escalating opioid dose.
Of note, if opioids are taken in intravenous form, as they often are when abused, individuals increase their risk of infections, human immunodeficiency virus, and hepatitis C virus exposure.
Opioids have relative contraindications, and each patient should have an appropriate assessment before discerning whether to administer opioids. For example, opioids are known to cause respiratory depression. Administration of opioids to patients with head trauma should be done carefully, as the increased pCO2 from hypoventilation can induce vasodilation and increased intracranial pressure. As previously noted, patients with pulmonary dysfunction may not be able to compensate for opioid-induced respiratory depression. Opioids are also not the first analgesic of choice when patients are experiencing liver or kidney dysfunction, as poor excretion and metabolism may result in the accumulation of byproducts. Individuals with adrenal and thyroid deficiencies may be more sensitive to opioids.
Pregnancy is another relative contraindication as the fetus may show signs of dependency. Approximately 50% of babies develop neonatal abstinence syndrome when exposed to opioids while in the womb. Infants with neonatal abstinence syndrome may develop diarrhea, sweating, sneezing, crying, tachypnea, and irritability.
Physicians often use urine drug screens for initial assessment, monitoring compliance, and documenting unusual drug behaviors when prescribing opioids. Another important tool is the Visual Analogue Scale (VAS), which is used to measure and monitor pain levels. However, there are some reported issues with VAS, including whether it is a ratio or ordinal level of pain measurement. Providers who treat patients with chronic opioid therapy should incorporate prescription drug monitoring program data into the treatment protocol.
The Clinical Opiate Withdrawal Scale (COWS) is a useful tool to evaluate individuals experiencing opioid withdrawal. Clinicians score withdrawal symptoms, which include yawning, rhinorrhea, and restlessness, and physiological measures, such as pulse rate, pupil size, and blood pressure to assess a patient’s level of withdrawal and infer his or her level of dependence on opioids.
Naloxone, a nonselective opioid antagonist, is used to treat the central nervous system and respiratory depression associated with opioid overdose. Nearly forty years ago, the FDA approved naloxone in injectable formulations to be used by trained professionals. Due to the increase in opioid overdoses, there has been an increased momentum to distribute naloxone to individuals using opioids who are at higher risk of overdose in the United States. The first program was started in Chicago in the mid-1990s and has since spread to many other cities and states. It is important to note that naloxone may precipitate withdrawal symptoms.
The US FDA has approved three drugs to treat opioid dependence: methadone, buprenorphine, and naltrexone. Methadone is a long-acting mu agonist used to treat opioid withdrawal symptoms and cravings. Currently, methadone is only dispensed by licensed treatment programs or methadone clinics. The abrupt discontinuation of methadone may result in acute withdrawal symptoms; therefore, discontinuation requires slow tapering.
Buprenorphine, a long-acting partial mu agonist and kappa antagonist, reduces cravings and withdrawal symptoms. It can be prescribed by physicians and nurses who have a Drug Abuse Treatment Act 200 X waiver. Abrupt discontinuation can also result in withdrawal.
Naltrexone is a mu receptor antagonist which does not require a special license or waiver for clinicians to prescribe it. Before using naltrexone to treat withdrawal or abstinence from opioids, patients must discontinue opioid use to detoxify, which can be challenging for some patients. Naltrexone has been successful in treating alcohol, nicotine, and stimulant use disorder.
However, research has revealed that conventional therapies like methadone or buprenorphine and naloxone do not work for all individuals with opioid use disorder, resulting in approximately 50% of patients suffering from relapse following treatment. Novel treatments, including a kappa-opioid receptor and serotonin modulator, as well as a vaccine that recruits the immune system to block opioid entry into the central nervous system, provide promising areas of research.
To provide optimum care to individuals who may require opioid therapy, physicians should follow a multimodal and an interprofessional approach. Prescribers must work with other healthcare professionals and team up with the patient. According to the CDC's guidelines, which are supported by the FDA, a few approaches that physicians can use include:
The most common form of diversion for prescription opioids includes patients providing medication to family members or friends who are attempting to self-medicate for pain. To combat this issue, prescribers must educate patients on the dangers of sharing medication and the importance of safely storing and disposing of medication.
The FDA also requires pharmaceutical companies who manufacture opioids to develop a training program that would teach prescribers how to decide which patients require opioid therapy, how to dose and monitor medication, and how to educate patients on safe use, disposal, and storage of the medication. CME credits and other incentives are offered to prescribers who attend the training. Companies are also required to provide patient education sheets that physicians can provide to patients on opioid therapy. Moreover, in July of 2019, the FDA adopted a drug safety program called Risk Evaluation and Mitigation Strategy (REMS) for extended-release and long-acting opioids in hopes of decreasing the risks from inappropriate prescribing and abuse of opioids while allowing patients who need opioid therapy to get the treatment they deserve.
Therapeutic opioid therapy requires the efforts and surveillance of the entire interprofessional health care team. Clinicians must follow the concepts outlined above when prescribing these agents. Nurses should counsel and also be vigilant for signs of "drug-seeking" behavior, and inform the prescriber if there are any concerns. The pharmacist may be best positioned to spot potential misuse since their position serves as the distribution point for the drug; it may be possible to notice "doctor shopping" behavior and report such to the prescribers. All members need ot collaborate in these efforts, with a focus on ensuring that those patients who actually need and can benefit from opioid therapy get the treatment they need and deserve. [Level 5]
|||Jamison RN,Mao J, Opioid Analgesics. Mayo Clinic proceedings. 2015 Jul; [PubMed PMID: 26141334]|
|||Camilleri M,Lembo A,Katzka DA, Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2017 Sep; [PubMed PMID: 28529168]|
|||Benyamin R,Trescot AM,Datta S,Buenaventura R,Adlaka R,Sehgal N,Glaser SE,Vallejo R, Opioid complications and side effects. Pain physician. 2008 Mar; [PubMed PMID: 18443635]|
|||Vora A,Nadkar MY, Codeine: A Relook at the Old Antitussive. The Journal of the Association of Physicians of India. 2015 Apr; [PubMed PMID: 26591180]|
|||Kaye AD,Jones MR,Kaye AM,Ripoll JG,Galan V,Beakley BD,Calixto F,Bolden JL,Urman RD,Manchikanti L, Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse: Part 1. Pain physician. 2017 Feb [PubMed PMID: 28226333]|
|||Volkow ND,McLellan AT, Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies. The New England journal of medicine. 2016 Mar 31 [PubMed PMID: 27028915]|
|||Jones GH,Bruera E,Abdi S,Kantarjian HM, The opioid epidemic in the United States-Overview, origins, and potential solutions. Cancer. 2018 Nov 15 [PubMed PMID: 30299538]|
|||Raffa RB, On subclasses of opioid analgesics. Current medical research and opinion. 2014 Dec; [PubMed PMID: 25105308]|
|||Chung KF, Clinical cough VI: the need for new therapies for cough: disease-specific and symptom-related antitussives. Handbook of experimental pharmacology. 2009; [PubMed PMID: 18825350]|
|||Green JL,Bucher Bartelson B,Le Lait MC,Roland CL,Masters ET,Mardekian J,Bailey JE,Dart RC, Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug and alcohol dependence. 2017 Jun 1; [PubMed PMID: 28414990]|
|||Crockett SD,Greer KB,Heidelbaugh JJ,Falck-Ytter Y,Hanson BJ,Sultan S, American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation. Gastroenterology. 2019 Jan; [PubMed PMID: 30340754]|
|||Volkow ND,Jones EB,Einstein EB,Wargo EM, Prevention and Treatment of Opioid Misuse and Addiction: A Review. JAMA psychiatry. 2019 Feb 1; [PubMed PMID: 30516809]|
|||Wilkerson RG,Kim HK,Windsor TA,Mareiniss DP, The Opioid Epidemic in the United States. Emergency medicine clinics of North America. 2016 May [PubMed PMID: 27133253]|
|||Izrailtyan I,Qiu J,Overdyk FJ,Erslon M,Gan TJ, Risk factors for cardiopulmonary and respiratory arrest in medical and surgical hospital patients on opioid analgesics and sedatives. PloS one. 2018; [PubMed PMID: 29566020]|
|||Epstein RA,Bobo WV,Martin PR,Morrow JA,Wang W,Chandrasekhar R,Cooper WO, Increasing pregnancy-related use of prescribed opioid analgesics. Annals of epidemiology. 2013 Aug; [PubMed PMID: 23889859]|
|||Kwong TC,Magnani B,Moore C, Urine and oral fluid drug testing in support of pain management. Critical reviews in clinical laboratory sciences. 2017 Sep; [PubMed PMID: 28990451]|
|||Heller GZ,Manuguerra M,Chow R, How to analyze the Visual Analogue Scale: Myths, truths and clinical relevance. Scandinavian journal of pain. 2016 Oct; [PubMed PMID: 28850536]|
|||Wesson DR,Ling W, The Clinical Opiate Withdrawal Scale (COWS). Journal of psychoactive drugs. 2003 Apr-Jun [PubMed PMID: 12924748]|
|||Ryan SA,Dunne RB, Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review. Pain management. 2018 May; [PubMed PMID: 29683378]|
|||Aboujaoude E,Salame WO, Naltrexone: A Pan-Addiction Treatment? CNS drugs. 2016 Aug; [PubMed PMID: 27401883]|
|||Baker DW, Improving Pain Management and Safe Use of Opioids: A Call for Papers. Joint Commission journal on quality and patient safety. 2017 Sep; [PubMed PMID: 28844235]|
|||Guy GP Jr,Zhang K,Bohm MK,Losby J,Lewis B,Young R,Murphy LB,Dowell D, Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015. MMWR. Morbidity and mortality weekly report. 2017 Jul 7; [PubMed PMID: 28683056]|
|||Dowell D,Haegerich TM,Chou R, CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016 Apr 19; [PubMed PMID: 26977696]|
|||Lim JK,Bratberg JP,Davis CS,Green TC,Walley AY, Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists. Journal of addiction medicine. 2016 Sep-Oct; [PubMed PMID: 27261669]|
|||Kuehn BM, FDA opioid safety plan promotes patient, physician education to prevent abuse. JAMA. 2010 Aug 25 [PubMed PMID: 20736462]|
|||[PubMed PMID: 27373304]|